drugset / Trial / NCT00037648

Juvenile Rheumatoid Arthritis

NCT00037648

Phase 2 Completed 86 enrolled Amgen
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the safety of anakinra in patients with Polyarticular-Course Juvenile Rheumatoid Arthritis, a form of rheumatoid arthritis affecting children.

Timeline

Start
2000-07
Primary completion
2003-11
Completion
2003-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Anakinra Protein / enzyme biologic Subcutaneous